MCID: INV001
MIFTS: 52

Invasive Aspergillosis

Categories: Genetic diseases, Immune diseases, Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Invasive Aspergillosis

MalaCards integrated aliases for Invasive Aspergillosis:

Name: Invasive Aspergillosis 12 15 74
Aspergillosis Invasive 56

Classifications:



External Ids:

Disease Ontology 12 DOID:0050073
UMLS 74 C0238013

Summaries for Invasive Aspergillosis

Disease Ontology : 12 An aspergillosis that is a serious fungal infection of the lung with pneumonia caused by Aspergillus, which spreads to other parts of the body through bloodstream in patients with acute leukemia and recipients of tissue transplants. Clinical symptoms include pulmonary nodules and hemorrhage.

MalaCards based summary : Invasive Aspergillosis, also known as aspergillosis invasive, is related to aspergillosis and candidiasis. An important gene associated with Invasive Aspergillosis is CLEC7A (C-Type Lectin Domain Containing 7A), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Caspofungin and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Invasive Aspergillosis

Diseases in the Aspergillosis family:

Invasive Aspergillosis

Diseases related to Invasive Aspergillosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 aspergillosis 32.4 CLEC7A IFNG MBL2 SFTPD TLR2 TLR4
2 candidiasis 30.8 CLEC7A IFNG MBL2
3 cystic fibrosis 30.0 CXCL8 MBL2 SFTPD TLR4
4 colitis 29.9 CXCL8 IFNG TLR4
5 legionellosis 29.8 TLR2 TLR4 TLR5
6 ulcerative colitis 29.7 CXCL8 IFNG TLR4
7 pulmonary disease, chronic obstructive 29.2 CXCL10 CXCL8 SFTPD TLR2
8 pneumonia 29.2 CXCL8 MBL2 SFTPD TLR2 TLR4 TLR5
9 systemic lupus erythematosus 29.1 CXCL10 IFNG MBL2 TLR2 TLR4 TLR5
10 rheumatoid arthritis 29.1 CXCL8 IFNG TLR2 TLR4
11 lung disease 28.9 CXCL10 CXCL8 MBL2 SFTPD TLR2
12 malaria 28.1 CXCL10 CXCL8 HBB IFNG TLR2 TLR4
13 leukemia 10.6
14 variola major 10.4 IFNG TLR4
15 hematopoietic stem cell transplantation 10.4
16 campylobacteriosis 10.3 IFNG TLR4
17 leukemia, acute myeloid 10.3
18 chronic granulomatous disease 10.3
19 myeloid leukemia 10.3
20 pericardial tuberculosis 10.3 CABIN1 IFNG
21 coccidioidomycosis 10.3 CLEC7A MBL2 TLR4
22 urethritis 10.2 TLR1 TLR6
23 mucormycosis 10.2
24 common wart 10.2 CLEC7A CXCL8
25 trench fever 10.2 TLR2 TLR4
26 pouchitis 10.2 CXCL8 TLR4
27 neutropenia 10.2
28 lymphocytic leukemia 10.2
29 clonorchiasis 10.2 CXCL8 IFNG
30 scabies 10.2 CXCL8 MBL2
31 ocular toxoplasmosis 10.2 TLR1 TLR5
32 crohn's colitis 10.2 CXCL8 IFNG
33 acute leukemia 10.2
34 meconium aspiration syndrome 10.2 CXCL8 IFNG
35 superficial urinary bladder cancer 10.2 CXCL8 TLR4
36 ariboflavinosis 10.2 TLR4 TLR6
37 endometrial disease 10.2 CXCL8 TLR4
38 pyelitis 10.2 CXCL8 TLR4
39 tularemia 10.1 MBL2 TLR2
40 periodontosis 10.1 CXCL8 TLR4
41 fungal meningitis 10.1 CXCL10 IFNG
42 typhoid fever 10.1 IFNG TLR4 TLR5
43 primary systemic mycosis 10.1 CLEC7A IFNG TLR2
44 fungal keratitis 10.1 CLEC7A TLR2 TLR4
45 leishmaniasis 10.1 IFNG TLR2 TLR4
46 leukemia, acute lymphoblastic 10.1
47 lupus erythematosus 10.1
48 spondylarthropathy 10.1 TLR2 TLR4
49 opportunistic mycosis 10.1 CLEC7A IFNG TLR2
50 myositis fibrosa 10.1 IFNG TLR2 TLR4

Graphical network of the top 20 diseases related to Invasive Aspergillosis:



Diseases related to Invasive Aspergillosis

Symptoms & Phenotypes for Invasive Aspergillosis

GenomeRNAi Phenotypes related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

27 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.03 CLEC7A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.03 CLEC7A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.03 CLEC7A MBL2 TLR5
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.03 TLR4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.03 MBL2 TLR4 TLR6
6 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.03 TLR5
7 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.03 CLEC7A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.03 TLR6
9 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.03 CLEC7A TLR4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.03 CLEC7A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-143 10.03 CLEC7A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.03 CLEC7A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.03 CLEC7A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-158 10.03 CLEC7A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.03 CLEC7A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.03 TLR5
17 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.03 TLR4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.03 CLEC7A
19 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.03 TLR6
20 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.03 CLEC7A MBL2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.03 CLEC7A
22 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.03 CLEC7A MBL2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.03 TLR5 TLR4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.03 CLEC7A
25 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.03 CLEC7A
26 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.03 TLR5
27 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.03 MBL2 TLR6
28 Increased shRNA abundance (Z-score > 2) GR00366-A-44 10.03 TLR5
29 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10.03 TLR5
30 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.03 MBL2 TLR5
31 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.03 CLEC7A
32 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.03 CLEC7A TLR5
33 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.03 TLR6
34 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.03 CLEC7A

MGI Mouse Phenotypes related to Invasive Aspergillosis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 CABIN1 CLEC7A CXCL10 IFNG MBL2 SFTPD
2 immune system MP:0005387 9.7 CABIN1 CLEC7A CXCL10 IFNG MBL2 SFTPD
3 respiratory system MP:0005388 9.1 CLEC7A IFNG SFTPD TLR2 TLR4 TLR5

Drugs & Therapeutics for Invasive Aspergillosis

Drugs for Invasive Aspergillosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caspofungin Approved Phase 4,Phase 3,Phase 2,Not Applicable 179463-17-3, 162808-62-0 2826718 468682
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137234-62-9 71616
4
Amphotericin B Approved, Investigational Phase 4,Phase 2,Phase 3 1397-89-3 14956 5280965
5
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 477468 3081921
6
Anidulafungin Approved, Investigational Phase 4,Phase 3,Phase 2 166663-25-8 166548
7
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 171228-49-2 147912
8
Mycophenolic acid Approved Phase 4 24280-93-1 446541
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
Itraconazole Approved, Investigational Phase 4,Phase 3 84625-61-6 55283
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Liposomal amphotericin B Phase 4,Phase 2,Phase 3
20 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
21 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Immunosuppressive Agents Phase 4,Phase 1
24
Hydroxyitraconazole Phase 4,Phase 3
25 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Pharmaceutical Solutions Phase 4,Phase 3
27 glucocorticoids Phase 4,Phase 3
28
Midazolam Approved, Illicit Phase 2, Phase 3,Phase 1 59467-70-8 4192
29
Isavuconazole Approved, Investigational Phase 3,Phase 2 241479-67-4
30
deoxycholic acid Approved Phase 3 83-44-3 222528
31
Fluconazole Approved, Investigational Phase 3,Phase 1,Not Applicable 86386-73-4 3365
32
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
33
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
34
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
35 Cholagogues and Choleretics Phase 3
36 Gastrointestinal Agents Phase 3,Phase 1
37 Amphotericin B, deoxycholate drug combination Phase 3
38 Cytochrome P-450 CYP2C19 Inhibitors Phase 3,Phase 1,Not Applicable
39 Peripheral Nervous System Agents Phase 3
40 Antiviral Agents Phase 3,Phase 2
41 Analgesics Phase 3
42 Anti-Retroviral Agents Phase 3
43 Interleukin-2 Phase 3
44 Analgesics, Non-Narcotic Phase 3
45 Anti-HIV Agents Phase 3
46
protease inhibitors Phase 3
47 Autonomic Agents Phase 3
48 BB 1101 Phase 3
49 HIV Protease Inhibitors Phase 3
50 Anti-Inflammatory Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 96)
# Name Status NCT ID Phase Drugs
1 COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis Completed NCT00334412 Phase 4 Ambisome;caspofungin
2 Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis Terminated NCT02646774 Phase 4 Micafungin
3 Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene) Terminated NCT00620074 Phase 4 voriconazole;anidulafungin
4 A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis Withdrawn NCT00423163 Phase 4 micafungin;voriconazole
5 CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels Recruiting NCT03731169 Phase 4 Standard of Care
6 King's Invasive Aspergillosis Study II Active, not recruiting NCT02875743 Phase 4 Posaconazole
7 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4 Itraconazole
8 Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants Not yet recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
9 A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children Terminated NCT00836875 Phase 3 Voriconazole
10 A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients Completed NCT00163722 Phase 3
11 Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis Completed NCT00531479 Phase 3 voriconazole;anidulafungin;voriconazole
12 A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA). Completed NCT00037206 Phase 2, Phase 3 Anidulafungin, VER002
13 A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069) Recruiting NCT01782131 Phase 3 Posaconazole;Voriconazole
14 Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects Withdrawn NCT01188759 Phase 3 Voriconazole;Anidulafungin;Voriconazole
15 Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis Completed NCT00001646 Phase 3 Voriconazole;Amphotericin B
16 Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment Completed NCT00158730 Phase 3 AmBisome
17 Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis Completed NCT00412893 Phase 3 Isavuconazole;Voriconazole
18 Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis Completed NCT00263315 Phase 2, Phase 3 nebulised liposomal amphotericin B
19 To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early Completed NCT00361517 Phase 3 Amphotericin-B deoxycholate
20 Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis Completed NCT00003031 Phase 3 amphotericin B deoxycholate;voriconazole
21 Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®) Completed NCT00177684 Phase 3 Amphotericin B
22 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
23 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
24 Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101) Completed NCT02180165 Phase 3 Posaconazole;Voriconazole
25 Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study) Completed NCT00627393 Phase 3 Standard antimicrobial therapy;G-CSF/dexamethasone
26 A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV
27 Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi Completed NCT00634049 Phase 3 isavuconazole
28 Prophylaxis With Caspofungin in High-Risk Liver Transplantation Unknown status NCT00333645 Phase 2 Caspofungin
29 Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis Completed NCT00404092 Phase 2 caspofungin
30 Micafungin Salvage Mono-therapy in Invasive Aspergillosis Terminated NCT00376337 Phase 2 Micafungin;Systemic antifungal therapy
31 VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults Terminated NCT03327727 Phase 2 Investigational Agent: VL-2397;Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
32 A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants Not yet recruiting NCT03816176 Phase 2 Isavuconazonium sulfate
33 Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis Withdrawn NCT01207128 Phase 2 Voriconazole, micafungin
34 MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037) Completed NCT00076869 Phase 2 MK0991, caspofungin acetate;Comparator: amphotericin B;Comparator: lipid formulation of amphotericin B and/or azole
35 Study of FK463 for the Treatment of Invasive Aspergillosis Completed NCT00036166 Phase 2 FK463
36 Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis Terminated NCT00047827 Phase 2 Micafungin;Liposomal Amphotericin B
37 Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections Completed NCT00059878 Phase 2 voriconazole
38 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
39 Prophylaxis of Fungal Invasive Infections in Leukemia Completed NCT00501098 Phase 2 Caspofungin
40 Study of Isavuconazole Prophylaxis in Adults With Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) and Neutropenia Recruiting NCT03019939 Phase 2 Isavuconazole
41 Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options Recruiting NCT03583164 Phase 2 F901318
42 Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis Completed NCT00391014 Phase 2 liposomal Amphotericine B
43 Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia Completed NCT01615809 Phase 2 AMPHOTERICIN B
44 F901318 Multiple Ascending Dose Study Completed NCT02342574 Phase 1 F901318;Placebo
45 Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects Completed NCT03340597 Phase 1 F901318
46 Drug/Drug Interactions With F901318 Withdrawn NCT03095547 Phase 1 cyclosporine A;Posaconazole;Pantoprazole;F901318;Tacrolimus
47 Pharmacokinetics of IV Formulation Withdrawn NCT03076905 Phase 1 F901318
48 Radiolabelled IV and Oral Metabolism Study of F901318 Not yet recruiting NCT02912026 Phase 1 IV F901318;Oral F901318
49 Evaluation of Immediate Release Tablet Completed NCT02808741 Phase 1 F901318 SDD;F901318 IR;F901318 IR Fasting;F901318 IR Fed
50 Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects Completed NCT02737371 Phase 1 F901318 Dose level A oral;Placebo dose level A oral;F901318 Dose level B oral;Placebo dose level B oral;F901318 Dose level C oral;Placebo Dose level C oral

Search NIH Clinical Center for Invasive Aspergillosis

Genetic Tests for Invasive Aspergillosis

Anatomical Context for Invasive Aspergillosis

MalaCards organs/tissues related to Invasive Aspergillosis:

42
Lung, Testes, Liver, Myeloid, Bone, Bone Marrow, Heart

Publications for Invasive Aspergillosis

Articles related to Invasive Aspergillosis:

(show top 50) (show all 1332)
# Title Authors Year
1
Prevention of healthcare-associated invasive aspergillosis during hospital construction/renovation works. ( 30629998 )
2019
2
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. ( 30649413 )
2019
3
International Multicenter Experience in the Treatment Outcome of Invasive Aspergillosis in Immunocompromised Cancer Patients. ( 30671209 )
2019
4
Invasive aspergillosis complicating treatment with tyrosine kinase inhibitors. ( 30700454 )
2019
5
Invasive aspergillosis manifesting as retinal necrosis in a patient treated with ruxolitinib. ( 30712951 )
2019
6
Correction: Combination Antifungal Therapy for Invasive Aspergillosis. ( 30716753 )
2019
7
Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden. ( 30744563 )
2019
8
Use of Aspergillus fumigatus real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: the need for a combined use with galactomannan. ( 30753590 )
2019
9
Invasive Aspergillosis in Pediatric Leukemia Patients: Prevention and Treatment. ( 30754630 )
2019
10
Subacute invasive aspergillosis in a patient with cystic fibrosis. ( 30765333 )
2019
11
The Difficulty of Diagnosing Invasive Aspergillosis Initially Manifesting as Optic Neuropathy. ( 30792652 )
2019
12
Why are so many cases of invasive aspergillosis missed? ( 30816963 )
2019
13
How to make a fast diagnosis in invasive aspergillosis. ( 30816965 )
2019
14
Clinical-scale production of Aspergillus-specific T cells for the treatment of invasive aspergillosis in the immunocompromised host. ( 30867554 )
2019
15
Invasive Aspergillosis in Solid Organ Transplant Recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. ( 30900296 )
2019
16
Mainly Post-Transplant Factors Are Associated with Invasive Aspergillosis after Allogeneic Stem Cell Transplantation: A Study from the Surveillance des Aspergilloses Invasives en France and Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. ( 30268782 )
2019
17
The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol. ( 29687483 )
2018
18
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. ( 29750016 )
2018
19
Performance of serum (1,3)-A9-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies. ( 29693758 )
2018
20
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. ( 29437588 )
2018
21
Subacute invasive aspergillosis associated with sorafenib therapy for hepatocellular carcinoma. ( 29370392 )
2018
22
Predicting Invasive Aspergillosis in Hematology Patients by Combining Clinical and Genetic Risk Factors with Early Diagnostic Biomarkers. ( 29118175 )
2018
23
How we approach combination antifungal therapy for invasive aspergillosis and mucormycosis in transplant recipients. ( 29975240 )
2018
24
Chitinase Induction Prior to Caspofungin Treatment of Experimental Invasive Aspergillosis in Neutropenic Rats Does Not Enhance Survival. ( 29084744 )
2018
25
Cost-effectiveness analysis of interventions for prevention of invasive aspergillosis among leukemia patients during hospital construction activities. ( 29105850 )
2018
26
Invasive aspergillosis in patients following umbilical cord blood transplant. ( 29795425 )
2018
27
Genetic deficiency of NOD2 confers resistance to invasive aspergillosis. ( 29980664 )
2018
28
Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis. ( 29928481 )
2018
29
Galactomannan antigenemia as a biomarker for therapeutic response of invasive aspergillosis: implications for clinical trial design and patient care. ( 29897826 )
2018
30
Multiple small bowel perforations due to invasive aspergillosis in a patient with acute myeloid leukemia: case report and a systematic review of the literature. ( 29357049 )
2018
31
Diagnosis of Invasive Aspergillosis in Hematological Malignancy Patients: Performance of Cytokines, Asp LFD, and Aspergillus PCR in Same Day Blood and Bronchoalveolar Lavage Samples. ( 29972764 )
2018
32
The burden of Invasive Aspergillosis in patients with haematological malignancy: A meta-analysis and systematic review. ( 29727605 )
2018
33
Invasive Aspergillosis Mimicking Metastatic Lung Cancer. ( 29922593 )
2018
34
Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age. ( 29670608 )
2018
35
Invasive Aspergillosis with Pulmonary and Central Nervous System involvement during ibrutinib therapy for relapsed Chronic Lymphocytic Leukaemia, a case report. ( 29427802 )
2018
36
Epidemiology and Outcomes of Hospitalizations With Invasive Aspergillosis in the United States, 2009-2013. ( 29718296 )
2018
37
Characterisation of the cellular and proteomic response of Galleria mellonella larvae to the development of invasive aspergillosis. ( 29954319 )
2018
38
Outbreak of invasive aspergillosis in heart transplant recipients: The role of screening computed tomography scans in asymptomatic patients and universal antifungal prophylaxis. ( 29125713 )
2018
39
Massive haemoptysis secondary to mycotic pulmonary artery aneurysm in subacute invasive aspergillosis. ( 29674397 )
2018
40
Local retrospective analysis of galactomannan cut-off values in bronchoalveolar lavage fluids for diagnosis of invasive aspergillosis. ( 29846912 )
2018
41
Production of the Invasive Aspergillosis Biomarker Bis(methylthio)gliotoxin Within the Genus <i>Aspergillus: In Vitro and in Vivo</i> Metabolite Quantification and Genomic Analysis. ( 29946309 )
2018
42
Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study. ( 29394399 )
2018
43
Improving the diagnosis of invasive aspergillosis by the detection of Aspergillus in broncho-alveolar lavage fluid: Comparison of non-culture-based assays. ( 29248586 )
2018
44
Use of Galactomannan Antigen and Aspergillus DNA Real-time Polymerase Chain Reaction as Routine Methods for Invasive Aspergillosis in Immunosuppressed Children in Greece. ( 29807668 )
2018
45
Urine Antigen Detection as an Aid to Diagnose Invasive Aspergillosis. ( 29684106 )
2018
46
Serum galactomannan antigen as a prognostic and diagnostic marker for invasive aspergillosis in heterogeneous medicine ICU patient population. ( 29684057 )
2018
47
Applying host disease status biomarkers to therapeutic response monitoring in invasive aspergillosis patients. ( 29370415 )
2018
48
Is Aspergillus lateral device ready to implement to the daily practice? The question rising from the new European Invasive Aspergillosis management guideline. ( 30522893 )
2018
49
Treating invasive aspergillosis in patients with hematologic malignancy: diagnostic-driven approach versus empiric therapies. ( 30545320 )
2018
50
Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: Aspergillus Galactomannan Lateral Flow Assay versus Aspergillus-specific Lateral Flow Device test in bronchoalveolar lavage. ( 30565352 )
2018

Variations for Invasive Aspergillosis

Expression for Invasive Aspergillosis

Search GEO for disease gene expression data for Invasive Aspergillosis.

Pathways for Invasive Aspergillosis

Pathways related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 CLEC7A CXCL10 CXCL8 HBB IFNG MBL2
2
Show member pathways
13.31 CXCL10 CXCL8 TLR1 TLR2 TLR4 TLR5
3
Show member pathways
13.11 IFNG TLR1 TLR2 TLR4 TLR5 TLR6
4
Show member pathways
12.68 CXCL10 CXCL8 IFNG MBL2 SFTPD TLR1
5
Show member pathways
12.63 TLR1 TLR2 TLR4 TLR5 TLR6
6
Show member pathways
12.62 CXCL10 CXCL8 IFNG TLR4
7
Show member pathways
12.55 TLR1 TLR2 TLR4 TLR5 TLR6
8 12.52 CABIN1 CXCL10 IFNG TLR1 TLR2 TLR6
9
Show member pathways
12.51 CXCL10 CXCL8 IFNG TLR2 TLR4
10
Show member pathways
12.49 IFNG TLR2 TLR4 TLR5
11
Show member pathways
12.39 TLR1 TLR2 TLR4 TLR6
12
Show member pathways
12.37 TLR1 TLR2 TLR4 TLR5 TLR6
13
Show member pathways
12.28 CXCL10 CXCL8 IFNG TLR2 TLR5
14
Show member pathways
12.21 CXCL8 TLR1 TLR2 TLR4 TLR5 TLR6
15
Show member pathways
12.16 CXCL10 CXCL8 TLR1 TLR2 TLR4 TLR5
16 12.16 CLEC7A IFNG TLR1 TLR2 TLR4 TLR6
17
Show member pathways
12.11 IFNG TLR2 TLR4
18 12.1 IFNG TLR1 TLR2 TLR4 TLR5 TLR6
19
Show member pathways
12.08 CXCL8 TLR2 TLR5
20 12.03 CLEC7A MBL2 SFTPD TLR2 TLR4 TLR6
21 11.99 CXCL10 CXCL8 IFNG TLR4
22
Show member pathways
11.99 IFNG TLR1 TLR2 TLR4 TLR6
23
Show member pathways
11.97 TLR1 TLR2 TLR4 TLR5 TLR6
24 11.87 CXCL8 IFNG TLR2 TLR4
25
Show member pathways
11.85 IFNG TLR1 TLR2 TLR4 TLR5 TLR6
26 11.84 CXCL8 IFNG TLR2 TLR4
27 11.8 CXCL8 IFNG TLR4 TLR5
28
Show member pathways
11.69 CABIN1 CXCL8 IFNG
29 11.58 CXCL8 TLR2 TLR4 TLR5
30 11.56 CLEC7A TLR1 TLR2 TLR4 TLR5 TLR6
31 11.49 IFNG TLR2 TLR4
32
Show member pathways
11.49 CXCL10 CXCL8 IFNG SFTPD TLR1 TLR2
33 11.41 CXCL8 HBB IFNG TLR2 TLR4
34 11.17 IFNG TLR1 TLR2

GO Terms for Invasive Aspergillosis

Cellular components related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phagocytic vesicle membrane GO:0030670 9.13 TLR1 TLR2 TLR6
2 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 8.62 TLR1 TLR2

Biological processes related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 IFNG TLR2 TLR4 TLR6
2 immune response GO:0006955 9.98 CXCL10 CXCL8 IFNG TLR1 TLR2 TLR4
3 innate immune response GO:0045087 9.97 CLEC7A MBL2 SFTPD TLR1 TLR2 TLR4
4 cellular response to lipopolysaccharide GO:0071222 9.9 CXCL10 CXCL8 TLR4 TLR5
5 response to lipopolysaccharide GO:0032496 9.88 CXCL10 TLR2 TLR4
6 defense response to bacterium GO:0042742 9.88 MBL2 SFTPD TLR4 TLR5 TLR6
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.87 TLR2 TLR4 TLR6
8 defense response GO:0006952 9.87 CXCL10 CXCL8 TLR1
9 positive regulation of nitric oxide biosynthetic process GO:0045429 9.72 HBB IFNG TLR4 TLR5 TLR6
10 cellular response to amyloid-beta GO:1904646 9.71 TLR4 TLR6
11 positive regulation of interferon-beta production GO:0032728 9.71 TLR2 TLR4
12 leukocyte chemotaxis GO:0030595 9.7 CXCL10 CXCL8
13 positive regulation of interleukin-10 production GO:0032733 9.7 TLR2 TLR4
14 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.7 TLR4 TLR6
15 positive regulation of chemokine production GO:0032722 9.69 TLR2 TLR4
16 positive regulation of interleukin-8 production GO:0032757 9.69 TLR2 TLR4 TLR5
17 microglial cell activation GO:0001774 9.68 TLR2 TLR6
18 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.68 TLR4 TLR6
19 positive regulation of macrophage activation GO:0043032 9.68 TLR4 TLR6
20 positive regulation of interleukin-8 secretion GO:2000484 9.68 TLR1 TLR2
21 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.67 TLR2 TLR4
22 positive regulation of reactive oxygen species biosynthetic process GO:1903428 9.67 TLR4 TLR6
23 I-kappaB phosphorylation GO:0007252 9.67 TLR2 TLR4
24 positive regulation of interleukin-12 production GO:0032735 9.67 IFNG TLR2 TLR4
25 negative regulation of interleukin-17 production GO:0032700 9.66 IFNG TLR4
26 response to molecule of bacterial origin GO:0002237 9.66 CXCL8 TLR2
27 macrophage activation GO:0042116 9.65 TLR1 TLR4
28 positive regulation of tumor necrosis factor biosynthetic process GO:0042535 9.65 TLR1 TLR4
29 toll-like receptor signaling pathway GO:0002224 9.65 SFTPD TLR1 TLR2 TLR4 TLR6
30 cellular response to lipoteichoic acid GO:0071223 9.64 TLR2 TLR4
31 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.64 TLR4 TLR6
32 interleukin-1 beta secretion GO:0050702 9.63 TLR4 TLR6
33 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.63 TLR1 TLR6
34 cell activation GO:0001775 9.63 TLR1 TLR2 TLR6
35 positive regulation of NLRP3 inflammasome complex assembly GO:1900227 9.62 TLR4 TLR6
36 cellular response to diacyl bacterial lipopeptide GO:0071726 9.62 TLR2 TLR6
37 positive regulation of toll-like receptor signaling pathway GO:0034123 9.61 TLR2 TLR5
38 toll-like receptor TLR6:TLR2 signaling pathway GO:0038124 9.61 TLR2 TLR6
39 cellular response to triacyl bacterial lipopeptide GO:0071727 9.59 TLR1 TLR2
40 nitric oxide metabolic process GO:0046209 9.58 TLR2 TLR6
41 positive regulation of oxidative stress-induced neuron death GO:1903223 9.58 TLR4 TLR6
42 toll-like receptor TLR1:TLR2 signaling pathway GO:0038123 9.57 TLR1 TLR2
43 detection of diacyl bacterial lipopeptide GO:0042496 9.56 TLR2 TLR6
44 inflammatory response GO:0006954 9.56 CLEC7A CXCL10 CXCL8 TLR1 TLR2 TLR4
45 detection of triacyl bacterial lipopeptide GO:0042495 9.55 TLR1 TLR2
46 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.55 TLR1 TLR2 TLR4 TLR5 TLR6
47 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.54 TLR2 TLR4
48 response to bacterial lipoprotein GO:0032493 9.52 TLR2 TLR6
49 regulation of cytokine secretion GO:0050707 9.02 TLR1 TLR2 TLR4 TLR5 TLR6
50 signal transduction GO:0007165 10.19 CXCL10 CXCL8 TLR1 TLR2 TLR4 TLR5

Molecular functions related to Invasive Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.76 TLR1 TLR2 TLR4 TLR6
2 signaling receptor binding GO:0005102 9.73 CXCL10 MBL2 TLR4 TLR6
3 signaling receptor activity GO:0038023 9.67 TLR1 TLR2 TLR4 TLR6
4 transmembrane signaling receptor activity GO:0004888 9.62 TLR1 TLR4 TLR5 TLR6
5 signaling pattern recognition receptor activity GO:0008329 9.4 CLEC7A TLR2
6 lipopolysaccharide receptor activity GO:0001875 9.26 TLR2 TLR4
7 Toll-like receptor 2 binding GO:0035663 9.16 TLR1 TLR6
8 lipopolysaccharide binding GO:0001530 9.13 SFTPD TLR2 TLR4
9 lipopeptide binding GO:0071723 8.8 TLR1 TLR2 TLR6

Sources for Invasive Aspergillosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....